Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Researchers sought to determine whether adding elotuzumab to PVd would be safe and effective in treating patients with relapsed or refractory MM.

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

AbbVie partners with Ichnos Glenmark to develop ISB 2001, a trispecific antibody for multiple myeloma, in a $1.9B licensing ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...